Lord, Abbett & Co’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-602,544
| Closed | -$56M | – | 714 |
|
|
2021
Q4 | $56M | Sell |
602,544
-167,129
| -22% | -$11M | 0.13% | 238 |
|
|
2021
Q3 | $45.8M | Sell |
769,673
-835,160
| -52% | -$49.3M | 0.11% | 277 |
|
|
2021
Q2 | $109M | Sell |
1,604,833
-420,015
| -21% | -$27.4M | 0.26% | 109 |
|
|
2021
Q1 | $141M | Buy |
2,024,848
+175,934
| +10% | +$13.5M | 0.36% | 67 |
|
|
2020
Q4 | $142M | Sell |
1,848,914
-164,870
| -8% | -$12.4M | 0.38% | 68 |
|
|
2020
Q3 | $151M | Buy |
2,013,784
+570,690
| +40% | +$38M | 0.48% | 42 |
|
|
2020
Q2 | $90.8M | Buy |
1,443,094
+592,384
| +70% | +$32.6M | 0.32% | 90 |
|
|
2020
Q1 | $35.7M | Buy |
+850,710
| New | +$39M | 0.16% | 197 |
|
|
2019
Q3 | – | Sell |
-76,690
| Closed | -$4.5M | – | 807 |
|
|
2019
Q2 | $4.5M | Sell |
76,690
-35,039
| -31% | -$1.81M | 0.01% | 660 |
|
|
2019
Q1 | $5.01M | Sell |
111,729
-2,567
| -2% | -$118K | 0.02% | 651 |
|
|
2018
Q4 | $4.45M | Buy |
114,296
+1,990
| +2% | +$78.1K | 0.02% | 670 |
|
|
2018
Q3 | $5.17M | Sell |
112,306
-22,068
| -16% | -$895K | 0.01% | 727 |
|
|
2018
Q2 | $5.86M | Buy |
134,374
+82,784
| +160% | +$3.56M | 0.02% | 714 |
|
|
2018
Q1 | $2.04M | Buy |
+51,590
| New | +$2.01M | 0.01% | 806 |
|
Lord, Abbett & Co's ARNA Position: Q1 2022 in Review
Lord, Abbett & Co sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 602,544 shares — an estimated $56M sold.
Lord, Abbett & Co first reported a position in ARNA in Q1 2018 and held it in 14 quarters. The position peaked at $151M in Q3 2020. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- Lord, Abbett & Co reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- Lord, Abbett & Co sold 602,544 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $56M.
- Lord, Abbett & Co first reported a position in Arena Pharmaceuticals Inc in Q1 2018 and held it in 14 quarters.
- Lord, Abbett & Co's Arena Pharmaceuticals Inc position peaked at $151M in Q3 2020.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on Lord, Abbett & Co's 13F filing for Q1 2022, filed 13 May 2022.